

## 510(k) Summary

Trade Name:	QuikClot® Nosebleed™
Device Class:	Class I
Classification Panel:	General and Plastic Surgery
Common Name:	Hemostatic Gauze
Classification Name:	Dressing
Classification Code:	FRO
Predicate Device:	QuikClot® eX™ (K072474)
Submitted By:	Ronald E. Peterson, Dir. of Regulatory Affairs and QA
Company Name:	Z-Medica Corporation
Company Address:	4 Fairfield Blvd., Wallingford, CT 06492
Company Phone:	+1-203-294-0000 x262
Prepared:	January 28, 2008

### Description of Device

The material composition of QuikClot® Nosebleed™ is identical to QuikClot® eX™. QuikClot® Nosebleed™ is a 2" x 2" four-ply Hemostatic Gauze and QuikClot® eX™ is a 4" x 4" four-ply Hemostatic Gauze Sponge.

### Indications for Use

For temporary use to control minor nosebleeds.  
(Over the Counter use)

### Discussion of Data to Support Substantial Equivalence

QuikClot® Nosebleed™ is identical to QuikClot® eX™ in composition and hemostatic performance. QuikClot® Nosebleed™ differs from QuikClot® eX™ only in size of device and QuikClot® Nosebleed™ has specific instructions for the nosebleed indication.

### Conclusion

Based on the device description and the specific labeling, QuikClot® Nosebleed™ is substantially equivalent to the predicate device and is safe and effective when temporarily used to stop minor nosebleeds.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room W-O66-0609  
Silver Spring, MD 20993-0002

JAN - 4 2010

Z-Medica Corporation  
% Ms. Mary McNamara-Cullinane  
Medical Device Consultants, Inc.  
49 Plain Street  
North Attleboro, Massachusetts 02760

Re: K080247  
Trade/Device Name: QuickClot<sup>®</sup> Nosebleed<sup>™</sup>  
Regulatory Class: Unclassified  
Regulation Name: Dressing  
Product Code: FRO  
Dated: January 23, 2008  
Received: January 30, 2008

Dear Ms. McNamara-Cullinane:

This letter corrects our substantially equivalent letter of February 27, 2008.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other

Page 2 – Ms. Mary McNamara-Cullinane

requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

  
D.E.O. Director

Mark N. Melkerson  
Director  
Division of Surgical, Orthopedic and  
Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Proposed Indications for Use

510(k) Number (if known): K080247

Device Trade Names: QuikClot® Nosebleed™

Device Common Name: Hemostatic Gauze

Indications for Use:

QuikClot® Nosebleed™ is intended for temporary use to control minor nosebleeds in children over 12 years of age and adults.


Prescription Use   
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use   
(Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)  
Division of Surgical, Orthopedic,  
and Restorative Devices

510(k) Number K080247